Edoxaban Noninferior to Dalteparin for Cancer-Associated VTE

The oral anticoagulant edoxaban appears noninferior to subcutaneous dalteparin for managing venous thromboembolism (VTE) in adults with cancer, according to an industry-supported, noninferiority trial...
Source: Physician's First Watch current issue - Category: Primary Care Source Type: news